机器学习方法预测抗血栓治疗患者胃肠道出血的比较效果
这项回顾性横断面研究利用OptumLabs数据仓库中306 463例2016年1月1日至2019年12月31日期间接受口服抗凝药和/或噻吩吡啶类抗血小板药的患者数据,比较了3种机器学习模型(RegCox、RSF、XGBoost)与HAS-BLED评分预测6个月和12个月胃肠道出血的性能。验证集中,RegCox和XGBoost的AUC在6个月均为0.67、12个月均为0.66,HAS-BLED为0.60和0.59,RSF为0.62和0.60。RegCox模型中重要性最高的变量为既往胃肠道出血(重要性评分0.72)、房颤/缺血性心脏病/静脉血栓栓塞症合并(0.38)和使用胃保护剂(0.32)。作者认为机器学习模型性能相似,两种模型略优于HAS-BLED,并建议前瞻性评估RegCox与HAS-BLED的临床影响。
要点
- 验证集中,RegCox模型预测胃肠道出血的AUC在6个月为0.67、12个月为0.66,XGBoost为0.67和0.66,均略高于HAS-BLED的0.60和0.59。
- RSF模型AUC在6个月为0.62、12个月为0.60,与HAS-BLED接近。
- RegCox模型中重要性评分最高的变量为既往胃肠道出血(0.72)、房颤/缺血性心脏病/静脉血栓栓塞症合并(0.38)和使用胃保护剂(0.32)。
- 整个队列中胃肠道出血发生率为4.0%(12 322/306 463),平均年龄69.0岁(SD 12.6),男性占54.2%,白人占63.2%。
- 作者认为,前瞻性评估RegCox模型与HAS-BLED的比较可能有助于理解性能提升的临床影响。
适用人群与场景
- 年龄≥18岁、有房颤、缺血性心脏病或静脉血栓栓塞症病史,且在2016年1月1日至2019年12月31日期间被开具口服抗凝药和/或噻吩吡啶类抗血小板药的患者。
- 数据来源为OptumLabs数据仓库,包含美国私人保险患者和Medicare Advantage参保者的医疗和药房索赔数据。
研究设计与关键结果
- 研究类型:回顾性横断面研究;样本量:306 463例;数据来源:OptumLabs数据仓库;人群:≥18岁有房颤、缺血性心脏病或静脉血栓栓塞症病史且接受口服抗凝药和/或噻吩吡啶类抗血小板药的患者;干预/对照:比较3种机器学习模型(RegCox、RSF、XGBoost)与HAS-BLED评分预测胃肠道出血的性能。
- 主要终点结果:验证集中,HAS-BLED预测胃肠道出血的AUC在6个月为0.60、12个月为0.59;RegCox模型AUC在6个月为0.67、12个月为0.66;XGBoost模型AUC在6个月为0.67、12个月为0.66;RSF模型AUC在6个月为0.62、12个月为0.60。
- RegCox模型中重要性评分最高的变量:既往胃肠道出血(重要性评分0.72);房颤、缺血性心脏病和静脉血栓栓塞症合并(重要性评分0.38);使用胃保护剂(重要性评分0.32)。
- 队列特征:男性166 177例(54.2%),白人193 648例(63.2%),平均年龄69.0岁(SD 12.6),发生胃肠道出血12 322例(4.0%)。
证据类型、等级与局限
- 证据类型:回顾性横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,机器学习模型在识别抗血栓药物处方后胃肠道出血高风险患者方面表现相似,其中RegCox和XGBoost两种模型略优于HAS-BLED评分。
- 作者认为,前瞻性评估RegCox模型与HAS-BLED的比较可能有助于更好地理解性能提升的临床影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Anticipating the risk of gastrointestinal bleeding (GIB) when initiating antithrombotic treatment (oral antiplatelets or anticoagulants) is limited by existing risk prediction models. Machine learning algorithms may result in superior predictive models to aid in clinical decision-making.
OBJECTIVE: To compare the performance of 3 machine learning approaches with the commonly used HAS-BLED (hypertension, abnormal kidney and liver function, stroke, bleeding, labile international normalized ratio, older age, and drug or alcohol use) risk score in predicting antithrombotic-related GIB.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cross-sectional study used data from the OptumLabs Data Warehouse, which contains medical and pharmacy claims on privately insured patients and Medicare Advantage enrollees in the US. The study cohort included patients 18 years or older with a history of atrial fibrillation, ischemic heart disease, or venous thromboembolism who were prescribed oral anticoagulant and/or thienopyridine antiplatelet agents between January 1, 2016, and December 31, 2019.
EXPOSURES: A cohort of patients prescribed oral anticoagulant and thienopyridine antiplatelet agents was divided into development and validation cohorts based on date of index prescription. The development cohort was used to train 3 machine learning models to predict GIB at 6 and 12 months: regularized Cox proportional hazards regression (RegCox), random survival forests (RSF), and extreme gradient boosting (XGBoost).
MAIN OUTCOMES AND MEASURES: The performance of the models for predicting GIB in the validation cohort, evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value, and prediction density plots. Relative importance scores were used to identify the variables that were most influential in the top-performing machine learning model.
RESULTS: In the entire study cohort of 306 463 patients, 166 177 (54.2%) were male, 193 648 (63.2%) were White, the mean (SD) age was 69.0 (12.6) years, and 12 322 (4.0%) had experienced a GIB. In the validation data set, the HAS-BLED model had an AUC of 0.60 for predicting GIB at 6 months and 0.59 at 12 months. The RegCox model performed the best in the validation set, with an AUC of 0.67 at 6 months and 0.66 at 12 months. XGBoost was similar, with AUCs of 0.67 at 6 months and 0.66 at 12 months, whereas for RSF, AUCs were 0.62 at 6 months and 0.60 at 12 months. The variables with the highest importance scores in the RegCox model were prior GI bleed (importance score, 0.72); atrial fibrillation, ischemic heart disease, and venous thromboembolism combined (importance score, 0.38); and use of gastroprotective agents (importance score, 0.32).
CONCLUSIONS AND RELEVANCE: In this cross-sectional study, the machine learning models examined showed similar performance in identifying patients at high risk for GIB after being prescribed antithrombotic agents. Two models (RegCox and XGBoost) performed modestly better than the HAS-BLED score. A prospective evaluation of the RegCox model compared with HAS-BLED may provide a better understanding of the clinical impact of improved performance.
参考来源
- Herrin J, Abraham NS, Yao X, et al. Comparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment. JAMA Netw Open. 2021. PMID: 34019087. doi:10.1001/jamanetworkopen.2021.10703
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。